InFlectis BioScience Doses First Patient with IFB-088 in a Phase 2 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
InFlectis BioScience Doses First Patient with IFB-088 in a Phase 2 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
Francina Agosti Inflectis Bioscience Reportable Inc Integrated Stress Response Amyotrophic Lateral Sclerosis Inflectis Bioscience
Source: parisguardian.com